Granules India Ltd

Granules India announced that the 35th Annual General Meeting(AGM) of the company will be held on 6 August 2026.

Granules India announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 1.75 per equity Share (i.e. 175%) , subject to the approval of the shareholders.

Granules India has fixed 30 July 2026 as record date for final dividend of Rs 1.75 per share for FY 2026.

Profit before exceptional items and tax increased 47.75% YoY to Rs 246.44 crore in Q4 FY26. Exceptional items stood at Rs 15.91 crore during the quarter. EBITDA stood at Rs 352.1 crore in Q4 FY26, registering the growth of 40%, compared with Rs 252.4 crore in Q4 FY25.EBITDA margin improved to 24% in Q4 FY26 as against 21% in Q4 FY25. Revenue from operations in Q4 FY26 was driven by finished dosages (FD) at 73%, followed by active pharmaceutical ingredients (API) at 13%, pharmaceutical formulation intermediates (PFI) at 9%, and peptide/CDMO at 5%. On a full-year basis, the company's consolidated net profit climbed 18.65% to Rs 595.02 crore on 19.73% increase in revenue from operations to Rs 5365.64 crore in FY26 over FY25. Krishna Prasad Chigurupati, chairman & managing director of Granules India said, 'We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform.' Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).

Net profit of Granules India rose 32.59% to Rs 201.57 crore in the quarter ended March 2026 as against Rs 152.03 crore during the previous quarter ended March 2025. Sales rose 21.78% to Rs 1457.43 crore in the quarter ended March 2026 as against Rs 1196.82 crore during the previous quarter ended March 2025. For the full year,net profit rose 18.64% to Rs 595.02 crore in the year ended March 2026 as against Rs 501.52 crore during the previous year ended March 2025. Sales rose 19.81% to Rs 5338.92 crore in the year ended March 2026 as against Rs 4455.97 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1457.431196.82 22 5338.924455.97 20 OPM %24.1621.09 -22.2021.21 - PBDT328.18230.30 43 1091.12854.92 28 PBT246.44166.80 48 794.98629.42 26 NP201.57152.03 33 595.02501.52 19 Powered by Capital Market - Live

Granules India will hold a meeting of the Board of Directors of the Company on 29 April 2026.

Granules Conusmer health is a wholly-owned subsidiary of Granules Pharmaceuticals, Inc and step-down subsidiary of the Granules India. It serves as Granules' front-end division for OTC products in the U.S., leveraging Granules India's manufacturing efficiencies, regulatory compliance, and integrated supply chain. The FDA inspection was conducted at the company's packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility's second FDA inspection, following the March 2023 audit, which also concluded with zero observations. Krishna Prasad Chigurupati, chairman and managing director of Granules India, said, 'Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects the strong culture of quality, safety and regulatory excellence demonstrated by our teams.' Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company reported a 27.73% jump in consolidated net profit to Rs 150.21 crore on 22% increase in revenue from operations to Rs 1,387.94 crore in Q3 FY26 over Q3 FY25.Powered by Capital Market - Live

Granules India announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc. has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) Status from the US Food and Drug Administration (FDA). The FDA inspection was conducted at the company's packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility's second FDA inspection, following the March 2023 audit, which also concluded with zero observations.Powered by Capital Market - Live

Revenue growth during the quarter was driven by Finished Dosages (FD) segment in North America and Europe. Profit before tax (PBT) jumped 32.36% YoY to Rs 202.23 crore during the quarter. EBITDA stood at Rs 308.1 crore, registering the growth of 34% compared with Rs 230.3 crore in Q3 FY25. EBITDA margin improved to 22% in Q3 FY26 as against 20% in Q3 FY25. For Q3 FY26, Finished Dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/CDMO contributed 76%, 11%, 11%, and 2% of revenue from operations, respectively. Net debt stood at Rs 1,015.1 crore and Net debt to EBITDA at 0.91x in Q3 FY26. Krishna Prasad Chigurupati, chairman & managing director of Granules India said, 'Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.' Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The scrip declined 1.09% to end at Rs 564.95 on the BSE.Powered by Capital Market - Live

Net profit of Granules India rose 27.73% to Rs 150.21 crore in the quarter ended December 2025 as against Rs 117.60 crore during the previous quarter ended December 2024. Sales rose 21.57% to Rs 1378.02 crore in the quarter ended December 2025 as against Rs 1133.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1378.021133.52 22 OPM %22.3620.32 - PBDT275.76209.40 32 PBT202.23152.79 32 NP150.21117.60 28 Powered by Capital Market - Live